"Bioelectronic Medicine Modifies Chronic Diseases With Doses Of Electricity" (MedTech Insight 2017)

Neurostimulation devices have been making a difference in the lives of patients for decades, when they entered common use for pain, epilepsy and other chronic conditions. These devices serve an important role, deliver- ing drugs or electric signals to mask pain or disrupt seizure patterns. However, they typically address symptoms and aren't usually able to address the underlying disease. Building on this foundation and converging with advances in bioengineering, immunology, neuroscience and understanding of disease mechanisms is the emerging field of bioelectronic medicine.

Like Comment
Page of
Go to the profile of SetPoint Medical

SetPoint Medical

SetPoint Medical is a privately held biomedical technology company dedicated to treating patients with debilitating inflammatory diseases using bioelectronic therapy. SetPoint’s approach is intended to offer patients and providers an alternative for the treatment of rheumatoid arthritis (RA) and other chronic inflammatory diseases with less risk and cost than drug therapy. SetPoint is developing a novel bioelectronic medicine platform that stimulates the vagus nerve to activate the body’s natural Inflammatory Reflex, which is intended to produce a potent systemic anti-inflammatory effect. The company has published positive results from a first-in-human open-label proof-of-concept trial in rheumatoid arthritis in Proceedings of the National Academy of Sciences (PNAS) and presented positive results at the American College of Rheumatology meeting. Current investors in the company include Morgenthaler Ventures, NEA, Topspin Partners, Medtronic, GlaxoSmithKline’s Action Potential Venture Capital Limited and Boston Scientific.

No comments yet.